US4271145A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Process for producing antibodies to hepatitis virus and cell lines therefor
Assignee: General Hospital Corp
•
Filing: 1979-10-22
•
Granted: 1981-06-02
•
Expires: 1999-10-22
Abstract
Abstract Cell lines for producing monoclonal antibodies to hepatitis virus are established by immunizing animal lymphocytes with hepatitis antigen to form antibody producing cells which then are fused with myeloma cells. The resultant somatic cell hybrids can be cloned. These clones produce monoclonal antibodies to individual antigenic determinates unique to hepatitis virus.
Inventors
- 👤 Jack R. Wands
- 👤 Vincent R. Zurawski, Jr.
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:54
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/08; Y; Y10; Y10S; Y10S435/00; Y10S435/8215; Y10S435/948; Y10S530/00; Y10S530/861; Y10S530/863; Y10S530/864
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
91 words
A process for preparing an antibody to a human viral hepatitis antigen which comprises intraperitoneally administering to an animal a first dosage of a hepatitis antigen in an amount of between approximately 1 and 50 μg/animal, intraveneously administering a second dosage of the hepatitis antigen to said animal at least about 3 weeks after administering said first dosage, recovering lymphocyte cells producing antibody from said animal, forming cell hybrids by fusing said lymphocyte cells to a myeloma cell, culturing said hybrids and collecting said antibody as a product of said hybrids.
Claim 2
Dependent Claim
91 words
A process for preparing an antibody to a human viral hepatitis antigen which comprises intraperitoneally administering to an animal a first dosage of a hepatitis antigen in an amount of between approximately 1 and 50 μg/animal, intraveneously administering a second dosage of the hepatitis antigen to said animal at least about 3 weeks after administering said first dosage, recovering lymphocyte cells producing antibody from said animal, forming cell hybrids by fusing said lymphocyte cells to a myeloma cell, culturing said hybrids and collecting said antibody as a product of said hybrids.
Claim 3
Dependent Claim
43 words
The process of claim 1 where the immunizing antigen is selected from the group consisting of Hepatitis B surface antigen (HBsAg), Hepatitis B core antigen (HBcAg), Hepatitis B e antigen (HBeAg), Hepatitis A virus (HAV), or viral antigens or non-A, non-B hepatitis virus(es).
Claim 4
Dependent Claim
30 words
The process of claim 1 wherein said hybrid is cultured in a histocompatable or immunocompromised animal and said antibody is recovered from the ascites fluid or serum of said animal.
Claim 5
Dependent Claim
14 words
The process of claim 1 wherein said hybrid is cloned and cultured in vitro.
Claim 6
Dependent Claim
11 words
The process of claim 3 wherein said hybrid is a clone.
Claim 7
Dependent Claim
20 words
The process of any one of claims 1, 2, 3, 4 or 5 wherein said lymphocyte cells are spleen cells.
Claim 8
Dependent Claim
29 words
The process of any one of claims 1, 2, 3, 4 or 5 wherein said lymphocyte cells are mouse spleen cells and said myeloma cells are mouse myeloma cells.
Claim 9
Dependent Claim
21 words
The process of any one of claims 1, 2, 3, 4 or 5 wherein said myeloma cells comprise mouse myeloma cells.
Claim 10
Dependent Claim
44 words
A compositon comprising a hybrid continuous cell line that produces antibody to a viral hepatitis antigen which comprises a cell hybrid of a BALB/c mouse spleen cell immunized with viral hepatitis antigen fused to a mouse myeloma and a culture medium for said hybrid.
Claim 11
Dependent Claim
44 words
A compositon comprising a hybrid continuous cell line that produces antibody to a viral hepatitis antigen which comprises a cell hybrid of a BALB/c mouse spleen cell immunized with viral hepatitis antigen fused to a mouse myeloma and a culture medium for said hybrid.
Claim 12
Dependent Claim
16 words
The composition of claim 9 wherein said hybrid is located in a culture medium containing hypoxanthine-aminopterinthymidine.
Claim 13
Dependent Claim
17 words
The composition of any one of claims 9 or 10 wherein said antibody is an IgG fraction.
Claim 14
Dependent Claim
17 words
The composition of any one of claims 9 or 10 wherein said antibody is an IgM fraction.
Claim 15
Dependent Claim
17 words
The composition of any one of claims 9 or 10 wherein said antibody is an IgA fraction.
References Cited (Backward Citations)
US4196265A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-06-01 | 1984-12-01 | 1985-06-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-06-01 | 1988-12-01 | 1989-06-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-06-01 | 1992-12-01 | 1993-06-02 | $7700.00 | Window Closed / Lapsed |